Over the years, doctors have used a variety of terms to classify the many different types of non-Hodgkin's lymphoma. Most often, they are grouped by how the cancer cells look under a microscope and how quickly they are likely to grow and spread. Aggressive lymphomas, also known as intermediate and high-grade lymphomas, tend to grow and spread quickly and cause severe symptoms. Indolent lymphomas, also referred to as low-grade lymphomas, tend to grow quite slowly and cause fewer symptoms. One of the paradoxes of non-Hodgkin's lymphoma is that ...

See also:

Non-Hodgkin lymphoma, Non-Hodgkin lymphoma - Symptoms, Non-Hodgkin lymphoma - Diagnosis, Non-Hodgkin lymphoma - Types of non-Hodgkin's lymphoma, Non-Hodgkin lymphoma - Etiology, Non-Hodgkin lymphoma - Staging, Non-Hodgkin lymphoma - Stages of NHL, Non-Hodgkin lymphoma - Treatment, Non-Hodgkin lymphoma - Clinical trials, Non-Hodgkin lymphoma - Nutrition, Non-Hodgkin lymphoma - Prognosis, Non-Hodgkin lymphoma - Followup care, Non-Hodgkin lymphoma - Etiology, Non-Hodgkin lymphoma - Notable NHL patients

Read more here: » Non-Hodgkin lymphoma: Encyclopedia II - Non-Hodgkin lymphoma - Types of non-Hodgkin's lymphoma

If non-Hodgkin's lymphoma is diagnosed, the doctor needs to learn the stage, or extent, of the disease. Staging is a careful attempt to find out whether the cancer has spread and, if so, what parts of the body are affected. Treatment decisions depend on these findings. The doctor considers the following to determine the stage of non-Hodgkin's lymphoma: The number and location of affected lymph nodes; Whether the affected lymph nodes are above, below, or on both sides of the diaphragm (the thin muscle under the lu ...

See also:

Non-Hodgkin lymphoma, Non-Hodgkin lymphoma - Symptoms, Non-Hodgkin lymphoma - Diagnosis, Non-Hodgkin lymphoma - Types of non-Hodgkin's lymphoma, Non-Hodgkin lymphoma - Etiology, Non-Hodgkin lymphoma - Staging, Non-Hodgkin lymphoma - Stages of NHL, Non-Hodgkin lymphoma - Treatment, Non-Hodgkin lymphoma - Clinical trials, Non-Hodgkin lymphoma - Nutrition, Non-Hodgkin lymphoma - Prognosis, Non-Hodgkin lymphoma - Followup care, Non-Hodgkin lymphoma - Etiology, Non-Hodgkin lymphoma - Notable NHL patients

Read more here: » Non-Hodgkin lymphoma: Encyclopedia II - Non-Hodgkin lymphoma - Staging

The doctor develops a treatment plan to fit each patient's needs. Treatment for non-Hodgkin's lymphoma depends on the stage of the disease, the type of cells involved, whether they are indolent or aggressive, and the age and general health of the patient. Non-Hodgkin's lymphoma is often treated by a team of specialists that may include a hematologist, medical oncologist, and/or radiation oncologist. Non-Hodgkin's lymphoma is usually treated with chemotherapy, radiation therapy, or a combination of these treatments. In some cases, bone ...

See also:

Non-Hodgkin lymphoma, Non-Hodgkin lymphoma - Symptoms, Non-Hodgkin lymphoma - Diagnosis, Non-Hodgkin lymphoma - Types of non-Hodgkin's lymphoma, Non-Hodgkin lymphoma - Etiology, Non-Hodgkin lymphoma - Staging, Non-Hodgkin lymphoma - Stages of NHL, Non-Hodgkin lymphoma - Treatment, Non-Hodgkin lymphoma - Clinical trials, Non-Hodgkin lymphoma - Nutrition, Non-Hodgkin lymphoma - Prognosis, Non-Hodgkin lymphoma - Followup care, Non-Hodgkin lymphoma - Etiology, Non-Hodgkin lymphoma - Notable NHL patients

Read more here: » Non-Hodgkin lymphoma: Encyclopedia II - Non-Hodgkin lymphoma - Treatment

Eating well during cancer treatment means getting enough food energy and protein to help prevent weight loss and regain strength. Good nutrition often helps people feel better and have more energy. Some people with cancer find it hard to eat a balanced diet because they may lose their appetite. In addition, common side effects of treatment, such as nausea, vomiting, or mouth sores, can make eating difficult. Often, foods taste different. Also, people being treated for cancer may not feel ...

See also:

Non-Hodgkin lymphoma, Non-Hodgkin lymphoma - Symptoms, Non-Hodgkin lymphoma - Diagnosis, Non-Hodgkin lymphoma - Types of non-Hodgkin's lymphoma, Non-Hodgkin lymphoma - Etiology, Non-Hodgkin lymphoma - Staging, Non-Hodgkin lymphoma - Stages of NHL, Non-Hodgkin lymphoma - Treatment, Non-Hodgkin lymphoma - Clinical trials, Non-Hodgkin lymphoma - Nutrition, Non-Hodgkin lymphoma - Prognosis, Non-Hodgkin lymphoma - Followup care, Non-Hodgkin lymphoma - Etiology, Non-Hodgkin lymphoma - Notable NHL patients

Read more here: » Non-Hodgkin lymphoma: Encyclopedia II - Non-Hodgkin lymphoma - Nutrition

Characteristic symptoms of MND include gradual weakening, wasting away, and uncontrollable twitching of the muscles; spasticity or stiffness in the arms and legs; and overactive tendon reflexes. Sensation, intellect, memory, and personality are not affected in MND. In some types of MND, such as ALS, muscle weakness is progressive and eventually leads to death when the muscles that control breathing no longer work. Oth ...

See also:

Motor neurone disease, Motor neurone disease - Terminology, Motor neurone disease - Signs and symptoms, Motor neurone disease - Diagnosis, Motor neurone disease - Pathology, Motor neurone disease - Causes, Motor neurone disease - Pathophysiology, Motor neurone disease - Extra-motor change in MND, Motor neurone disease - Epidemiology, Motor neurone disease - Prognosis, Motor neurone disease - Treatment, Motor neurone disease - Etymology, Motor neurone disease - History and prominent patients, Motor neurone disease - Sources and references, Motor neurone disease - Information about Clinical Trials, Motor neurone disease - Other Resources

Read more here: » Motor neurone disease: Encyclopedia II - Motor neurone disease - Signs and symptoms

The diagnosis of ALS is established based on the history of the patient and the findings on neurological examination. There is no diagnostic test for ALS. Electromyography (EMG) examination are useful to demonstrate the diffuse loss of motor neurones innervating muscles of extremities, face and abdomen and to rule out other disorders that may mimic ALS, but interpretation of the result is not necessarily straight forward. A set of diagnostic criteria called the El Escorial criteria have been defined by the World Federation of Neurologists and a ...

See also:

Motor neurone disease, Motor neurone disease - Terminology, Motor neurone disease - Signs and symptoms, Motor neurone disease - Diagnosis, Motor neurone disease - Pathology, Motor neurone disease - Causes, Motor neurone disease - Pathophysiology, Motor neurone disease - Extra-motor change in MND, Motor neurone disease - Epidemiology, Motor neurone disease - Prognosis, Motor neurone disease - Treatment, Motor neurone disease - Etymology, Motor neurone disease - History and prominent patients, Motor neurone disease - Sources and references, Motor neurone disease - Information about Clinical Trials, Motor neurone disease - Other Resources

Read more here: » Motor neurone disease: Encyclopedia II - Motor neurone disease - Diagnosis

Motor neurone disease - Causes. Nonhereditary (also called sporadic) MND are caused by unknown factors. Nonhereditary MND include ALS, progressive bulbar palsy, pseudobulbar palsy, primary lateral sclerosis, progressive muscular atrophy, and post-polio syndrome. There are no specific tests to diagnose the MND.[3] About 90% of cases of MND are "sporadic", meaning that the patient has no family history of ALS and the case appears to have occured sporadically in the community. The cause of sporadic ALS is unk ...

See also:

Motor neurone disease, Motor neurone disease - Terminology, Motor neurone disease - Signs and symptoms, Motor neurone disease - Diagnosis, Motor neurone disease - Pathology, Motor neurone disease - Causes, Motor neurone disease - Pathophysiology, Motor neurone disease - Extra-motor change in MND, Motor neurone disease - Epidemiology, Motor neurone disease - Prognosis, Motor neurone disease - Treatment, Motor neurone disease - Etymology, Motor neurone disease - History and prominent patients, Motor neurone disease - Sources and references, Motor neurone disease - Information about Clinical Trials, Motor neurone disease - Other Resources

Read more here: » Motor neurone disease: Encyclopedia II - Motor neurone disease - Pathology

Motor neurone disease - Causes. Nonhereditary (also called sporadic) MND are caused by unknown factors. Nonhereditary MND include ALS, progressive bulbar palsy, pseudobulbar palsy, primary lateral sclerosis, progressive muscular atrophy, and post-polio syndrome. There are no specific tests to diagnose the MND.[3] About 90% of cases of MND are "sporadic", meaning that the patient has no family history of ALS and the case appears to have occurred sporadically in the community. The cause of sporadic ALS is un ...

See also:

Motor neurone disease, Motor neurone disease - Terminology, Motor neurone disease - Signs and symptoms, Motor neurone disease - Diagnosis, Motor neurone disease - Pathology, Motor neurone disease - Causes, Motor neurone disease - Pathophysiology, Motor neurone disease - Extra-motor change in MND, Motor neurone disease - Epidemiology, Motor neurone disease - Prognosis, Motor neurone disease - Treatment, Motor neurone disease - Etymology, Motor neurone disease - History and prominent patients, Motor neurone disease - Sources and references, Motor neurone disease - Information about Clinical Trials, Motor neurone disease - Other Resources

Read more here: » Motor neurone disease: Encyclopedia II - Motor neurone disease - Pathology

Some medications only show to have safety issues after they are marketed, as clinical trials are of a limited size, such as the 3,000 test subjects required by the FDA. Post-marketing surveillance ensures that after marketing the safety of a drug is monitored closely. In certain instances, its indication may need to be limited to particular patient groups, and in others the substance is withdrawn from the market completely. After the FDA (or other regulatory agency for drugs marketed outside the U.S.) approves a new drug, pharmaceutic ...

See also:

Pharmaceutical company, Pharmaceutical company - History, Pharmaceutical company - Biotechnology company, Pharmaceutical company - Drug discovery, Pharmaceutical company - Target identification, Pharmaceutical company - Target prioritization/validation, Pharmaceutical company - Lead identification, Pharmaceutical company - Lead optimization, Pharmaceutical company - Drug development, Pharmaceutical company - Phase I Clinical Studies, Pharmaceutical company - Phase II Clinical Studies, Pharmaceutical company - Phase III Clinical Studies, Pharmaceutical company - New Drug Application, Pharmaceutical company - Orphan drug, Pharmaceutical company - Post-approval surveillance, Pharmaceutical company - Phase IIIb/IV Studies, Pharmaceutical company - Post-Market Studies, Pharmaceutical company - Products, Pharmaceutical company - Drug information, Pharmaceutical company - ICD and DRG, Pharmaceutical company - Revenues, Pharmaceutical company - Industry revenues, Pharmaceutical company - Patents and Generics, Pharmaceutical company - Medicare Part D, Pharmaceutical company - Sales and marketing, Pharmaceutical company - The pharmaceutical industry is different, Pharmaceutical company - Advertising to physicians, Pharmaceutical company - Direct to consumer, Pharmaceutical company - The payers, Pharmaceutical company - Mergers acquisitions and co-marketing of drugs, Pharmaceutical company - Controversy, Pharmaceutical company - Bibliography, Pharmaceutical company - Controversy, Pharmaceutical company - Drug discovery and development, Pharmaceutical company - Management mergers acquisitions co-marketing deals, Pharmaceutical company - Sales and marketing

Read more here: » Pharmaceutical company: Encyclopedia II - Pharmaceutical company - Post-approval surveillance

MND has three major subgroups: primary lateral sclerosis (PLS, only the upper motor neurones are affected), progressive muscular atrophy (PMA, only the lower motor neurons are affected) and amyotrophic lateral sclerosis (ALS, both types of motor neurons are affected). PLS and PMA each account for about 5% of cases, with the majority of diagnoses being ALS. The incidence of MND is approximately 1–5 out of 100,000 people. Men have a 20% higher rate of incidence than women. Approxima ...

See also:

Motor neurone disease, Motor neurone disease - Terminology, Motor neurone disease - Signs and symptoms, Motor neurone disease - Diagnosis, Motor neurone disease - Pathology, Motor neurone disease - Causes, Motor neurone disease - Pathophysiology, Motor neurone disease - Extra-motor change in MND, Motor neurone disease - Epidemiology, Motor neurone disease - Prognosis, Motor neurone disease - Treatment, Motor neurone disease - Etymology, Motor neurone disease - History and prominent patients, Motor neurone disease - Sources and references, Motor neurone disease - Information about Clinical Trials, Motor neurone disease - Other Resources

Read more here: » Motor neurone disease: Encyclopedia II - Motor neurone disease - Epidemiology

U.S. baseball player Lou Gehrig brought national and international attention to the disease in 1939 when he abruptly retired after being diagnosed with ALS/MND. Former guitar virtuoso Jason Becker, theoretical physicist Stephen Hawking, and ex-Celtic football player Jimmy Johnstone also suffer from the disease. Founder of care homes Leonard Cheshire VC, owner from 1957-1966 of Athelhampton House in Dorset Sir Robert Cooke F.R.C.S., theoretical physicist Victor Emery, Rangers footballer Sam English, Hall of Fame pitcher Jim "Catfish" H ...

See also:

Motor neurone disease, Motor neurone disease - Terminology, Motor neurone disease - Signs and symptoms, Motor neurone disease - Diagnosis, Motor neurone disease - Pathology, Motor neurone disease - Causes, Motor neurone disease - Pathophysiology, Motor neurone disease - Extra-motor change in MND, Motor neurone disease - Epidemiology, Motor neurone disease - Prognosis, Motor neurone disease - Treatment, Motor neurone disease - Etymology, Motor neurone disease - History and prominent patients, Motor neurone disease - Sources and references, Motor neurone disease - Information about Clinical Trials, Motor neurone disease - Other Resources

Read more here: » Motor neurone disease: Encyclopedia II - Motor neurone disease - History and prominent patients

Mortality in relation to smoking: 50 years' observation on male British doctors Authors: R. Doll, R. Peto, J. Boreham, I. Sutherland Publication data: BMJ 2004;328:1519–33. Description: This is the British doctors study. A prospective clinical trial which has been running from 1951 to 2001, and in 1956 provided convincing statistical evidence that tobacco smoking increases ...

See also:

List of publications in medicine, List of publications in medicine - Foundations, List of publications in medicine - Recent studies, List of publications in medicine - Bioethics, List of publications in medicine - Biostatistics, List of publications in medicine - Embryology, List of publications in medicine - Nutrition, List of publications in medicine - Transfusion medicine, List of publications in medicine - Clinical chemistry, List of publications in medicine - Hematology, List of publications in medicine - Radiology, List of publications in medicine - Interventional radiology, List of publications in medicine - Nuclear Medicine, List of publications in medicine - Anesthesiology, List of publications in medicine - Pain medicine, List of publications in medicine - Dermatology, List of publications in medicine - Emergency medicine, List of publications in medicine - General practice, List of publications in medicine - Geriatrics, List of publications in medicine - Hospital medicine, List of publications in medicine - Intensive care medicine, List of publications in medicine - Internal medicine, List of publications in medicine - Cardiology, List of publications in medicine - Gastroenterology, List of publications in medicine - Endocrinology, List of publications in medicine - Hematology, List of publications in medicine - Infectious diseases, List of publications in medicine - Nephrology, List of publications in medicine - Oncology, List of publications in medicine - Pulmonology, List of publications in medicine - Rheumatology, List of publications in medicine - Neurology, List of publications in medicine - Obstetrics, List of publications in medicine - gynecology, List of publications in medicine - Palliative care, List of publications in medicine - Pediatrics, List of publications in medicine - public health, List of publications in medicine - Psychiatry, List of publications in medicine - Radiation therapy, List of publications in medicine - General surgery, List of publications in medicine - Neurosurgery, List of publications in medicine - Ophthalmology, List of publications in medicine - Orthopedic surgery, List of publications in medicine - Otolaryngology, List of publications in medicine - Plastic surgery, List of publications in medicine - Urology, List of publications in medicine - Vascular surgery, List of publications in medicine - hyperbaric medicine, List of publications in medicine - Medical informatics, List of publications in medicine - Nosology

Read more here: » List of publications in medicine: Encyclopedia II - List of publications in medicine - Recent studies

Investigational New Drug (IND) Application: An application filed with the U.S. Food and Drug Administration (FDA) prior to human testing. The IND application is a compilation of all known information about the compound. It also includes a description of the clinical research plan for the product and the specific protocol for phase I human clinical trials. Unless the FDA specifically objects, the IND is automatically approv ...

See also:

Regulatory requirement, Regulatory requirement - Drug Discovery and Development, Regulatory requirement - Regulatory Review:, Regulatory requirement - Phase I Clinical Evaluation, Regulatory requirement - Phase II Clinical Evaluation, Regulatory requirement - Phase III Clinical Evaluation, Regulatory requirement - Regulatory Review: New Drug Application NDA, Regulatory requirement - Post approval

Read more here: » Regulatory requirement: Encyclopedia II - Regulatory requirement - Regulatory Review:

There are numerous fields that require the use of estimation theory. Some of these fields include (but by no means limited to): Medicine Clinical trials Imaging: CAT EEG EKG/ECG MRI Medical ultrasonography Opinion polls Quality control Radar, sonar Localization of objects Telecommunications Channel parameters Noise variance DC gain (see example below) See also:

Estimation theory, Estimation theory - Fields that use estimation theory, Estimation theory - Estimation process, Estimation theory - Basics, Estimation theory - Estimators, Estimation theory - Example: DC gain in white Gaussian noise, Estimation theory - Maximum likelihood, Estimation theory - Cramér-Rao lower bounds, Estimation theory - Books

Read more here: » Estimation theory: Encyclopedia II - Estimation theory - Fields that use estimation theory

IGF1 has been synthesized and used in therapeutic trials for several conditions including growth failure and diabetes. Results of clinical trials sponsored by Genentech in the 1990s were not considered promising enough to pursue. However, in the last few years, Tercica compiled enough clinical trial evidence to seek FDA approval in the United States. In August, 2005, the FDA approved Increlex as replacement therapy for severe IGF-1 deficiency based on clinical trial data from 71 patients. Data reported at the 2004 Annual Meeting of th ...

See also:

Insulin-like growth factor 1, Insulin-like growth factor 1 - Production and circulation, Insulin-like growth factor 1 - Action, Insulin-like growth factor 1 - Use as a diagnostic test, Insulin-like growth factor 1 - Diseases of deficiency and resistance, Insulin-like growth factor 1 - IGF1 as a therapeutic agent, Insulin-like growth factor 1 - Terminology

Read more here: » Insulin-like growth factor 1: Encyclopedia II - Insulin-like growth factor 1 - IGF1 as a therapeutic agent

Blood substitutes - Perfluorocarbon based. Oxygent, by Alliance Pharmaceutical. Status: U.S. phase II trials, European phase III trials Oxycyte, by Synthetic Blood International. Status: U.S. phase II trials PHER-02, by Sanguine Corp. Status: In research Perftoran (Russian). Status: approved for Russian clinical trials in 1996 Blood substitutes - Hemoglobin based. Hemopure, by Biopure Corp. Status: U.S. phase III trials, more widely ...

See also:

Blood substitutes, Blood substitutes - Volume expanders, Blood substitutes - Towards artificial blood, Blood substitutes - Advantages, Blood substitutes - Current oxygen therapeutics under development, Blood substitutes - Perfluorocarbon based, Blood substitutes - Hemoglobin based, Blood substitutes - Withdrawn oxygen therapeutics

Read more here: » Blood substitutes: Encyclopedia II - Blood substitutes - Current oxygen therapeutics under development

Whilst zanamivir proved to be a potent and effective inhibitor of influenza neuraminidase and inhibitor of influenza virus replication in vitro and in vivo, this didn't necessarily translate into a successful clinical treatment for influenza. In clinical trials it was found that zanamivir was able to reduce the time to symptom resolution by 1.5 days provided therapy was started within 48 hours of the onset of symptoms. A further limitation concerns the poor oral bioavailability of zanamivir. This meant that oral dosing w ...

See also:

Zanamivir, Zanamivir - Development, Zanamivir - Limitations, Zanamivir - A troubled commercial venture, Zanamivir - A prototype for others

Read more here: » Zanamivir: Encyclopedia II - Zanamivir - Limitations

Eflornithine (difluoromethylornithine or DFMO), the most modern treatment, was developed in the 1970s by Albert Sjoerdsmanot and underwent clinical trials in the 1980s. The drug was approved by the FDA in 1990, but Aventis, the company responsible for its manufacture, halted production in 1999. In 2001, however, Aventis, in association with Medecins Sans Frontieres and the WHO, signed a long-ter ...

See also:

Sleeping sickness, Sleeping sickness - History, Sleeping sickness - Geographic distribution and epidemiology, Sleeping sickness - Life cycle, Sleeping sickness - Clinical features, Sleeping sickness - Laboratory diagnosis, Sleeping sickness - Treatment, Sleeping sickness - Prevention and control

Read more here: » Sleeping sickness: Encyclopedia II - Sleeping sickness - Treatment

Controlled and uncontrolled clinical trial of a drug's safety and effectiveness in hospital and outpatient settings. Phase III studies gather precise information on the drug's effectiveness for specific indications, determine whether the drug produces a broader range of adverse effects than those exhibited in the small study populations of phase I and II studies, and identify the best way of administering and using the drug for the purpose intended. If the drug is approved, this information forms the basis for deciding the content of the product label. Pha ...

See also:

Regulatory requirement, Regulatory requirement - Drug Discovery and Development, Regulatory requirement - Regulatory Review:, Regulatory requirement - Phase I Clinical Evaluation, Regulatory requirement - Phase II Clinical Evaluation, Regulatory requirement - Phase III Clinical Evaluation, Regulatory requirement - Regulatory Review: New Drug Application NDA, Regulatory requirement - Post approval

Read more here: » Regulatory requirement: Encyclopedia II - Regulatory requirement - Phase III Clinical Evaluation

Critics of evidence-based medicine maintain that good evidence is often deficient in many areas, that lack of evidence and lack of benefit are not the same, and that the more data are pooled and aggregated, the more difficult it is to compare the patients in the studies with the patient in front of the doctor, i.e. EBM applies to populations, not necessarily to individuals. In The limits of evidence-based medicine, Tonelli argues that "the knowledge gained from clinical research does not directly answer the primary clinical question of what is best for the patient at hand." Tonelli suggests that ...

See also:

Evidence-based medicine, Evidence-based medicine - Overview, Evidence-based medicine - History, Evidence-based medicine - Qualification of evidence, Evidence-based medicine - Categories of recommendations, Evidence-based medicine - Limitations of available evidence, Evidence-based medicine - Criticism of evidence-based medicine, Evidence-based medicine - Note

Read more here: » Evidence-based medicine: Encyclopedia II - Evidence-based medicine - Criticism of evidence-based medicine

Systems to stratify evidence by quality have been developed, such as this one by the U.S. Preventive Services Task Force: Level I: Evidence obtained from at least one properly designed randomized controlled trial. Level II-1: Evidence obtained from well-designed controlled trials without randomization. Level II-2: Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group. Level II-3: Evidence obtained from multiple time series w ...

See also:

Evidence-based medicine, Evidence-based medicine - Overview, Evidence-based medicine - History, Evidence-based medicine - Qualification of evidence, Evidence-based medicine - Categories of recommendations, Evidence-based medicine - Limitations of available evidence, Evidence-based medicine - Criticism of evidence-based medicine, Evidence-based medicine - Note

Read more here: » Evidence-based medicine: Encyclopedia II - Evidence-based medicine - Qualification of evidence

In guidelines and other publications, recommendations are classified according to the level of evidence on which they are based. The U.S. Preventive Service Task Force uses: Level A: Recommendations are based on good and consistent scientific evidence. Level B: Recommendations are based on limited or inconsistent scientific evidence. Level C: Recommendations are based primarily on consensus and expert opinion. This is a distinct and conscious improvement on older fashions in recommendation and the interpretation of recommendations where i ...

See also:

Evidence-based medicine, Evidence-based medicine - Overview, Evidence-based medicine - History, Evidence-based medicine - Qualification of evidence, Evidence-based medicine - Categories of recommendations, Evidence-based medicine - Limitations of available evidence, Evidence-based medicine - Criticism of evidence-based medicine, Evidence-based medicine - Note

Read more here: » Evidence-based medicine: Encyclopedia II - Evidence-based medicine - Categories of recommendations